{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T18:22:35Z","timestamp":1776882155558,"version":"3.51.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,5,23]],"date-time":"2015-05-23T00:00:00Z","timestamp":1432339200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s13277-015-3564-2","type":"journal-article","created":{"date-parts":[[2015,5,22]],"date-time":"2015-05-22T14:44:59Z","timestamp":1432305899000},"page":"8277-8285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Serum markers in early-stage and locally advanced melanoma"],"prefix":"10.1007","volume":"36","author":[{"given":"Iwona","family":"Lugowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Kowalska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Fuksiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Kotowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Mierzejewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Kose\u0142a-Paterczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Szamotulska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,23]]},"reference":[{"issue":"36","key":"3564_CR1","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199\u2013206.","journal-title":"J Clin Oncol"},{"key":"3564_CR2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.seminoncol.2007.09.009","volume":"34","author":"GH Mahabeleshwar","year":"2007","unstructured":"Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Semin Oncol. 2007;34:555\u201365.","journal-title":"Semin Oncol"},{"key":"3564_CR3","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3389\/fphys.2013.00122","volume":"4","author":"R Shao","year":"2013","unstructured":"Shao R. YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol. 2013;4:122.","journal-title":"Front. Physiol."},{"key":"3564_CR4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.biochi.2005.01.013","volume":"87","author":"UB Hofmann","year":"2005","unstructured":"Hofmann UB, Houben R, Brocker EB, Becker JC. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie. 2005;87:307\u201314.","journal-title":"Biochimie"},{"key":"3564_CR5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00018-013-1457-3","volume":"71","author":"C Ries","year":"2014","unstructured":"Ries C. Cytokine functions of MMP-1. Cell Mol Life Sci. 2014;71:659\u201372.","journal-title":"Cell Mol Life Sci"},{"key":"3564_CR6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.humpath.2009.08.016","volume":"41","author":"J Mehnert","year":"2010","unstructured":"Mehnert J, McCarthy M, Jilaveanu L, et al. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol. 2010;41:375\u201384.","journal-title":"Hum Pathol"},{"key":"3564_CR7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1600-0560.2012.01955.x","volume":"39","author":"F Cianfarani","year":"2012","unstructured":"Cianfarani F, Mastroeni S, Odorisio T, et al. Expression of vascular endothelial growth factor-C in primary cutaneous melanoma predicts sentinel lymph node positivity. J Cutan Pathol. 2012;39:826\u201334.","journal-title":"J Cutan Pathol"},{"key":"3564_CR8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1523-1747.2000.00068.x","volume":"115","author":"UB Hofmann","year":"2000","unstructured":"Hofmann UB, Westphal JR, van Muijen GNP, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol. 2000;115:337\u201344.","journal-title":"J Invest Dermatol"},{"key":"3564_CR9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejcb.2014.01.002","volume":"93","author":"N Moro","year":"2014","unstructured":"Moro N, Mauch C, Zigrino P. Metalloproteinases in melanoma. Eur J Cell Biol. 2014;93:23\u20139.","journal-title":"Eur J Cell Biol"},{"key":"3564_CR10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2133.2005.06507.x","volume":"152","author":"F Pelletier","year":"2005","unstructured":"Pelletier F, Bermont L, Puzenat E, et al. Circulating vascular endothelial growth factor in cutaneous malignant melanoma. Br J Dermatol. 2005;152:685\u20139.","journal-title":"Br J Dermatol"},{"key":"3564_CR11","first-page":"4255","volume":"24","author":"PA Ascierto","year":"2004","unstructured":"Ascierto PA, Leonardi E, Ottaiano A, et al. Prognostic value of serum VEGF in melanoma patients: a pilot study. Anticancer Res. 2004;24:4255\u20138.","journal-title":"Anticancer Res"},{"key":"3564_CR12","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1158\/1078-0432.CCR-04-2478","volume":"11","author":"J Nikkola","year":"2005","unstructured":"Nikkola J, Vihinen P, Vuoristo MS, et al. High serum levels of MMP-9 and MMP-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res. 2005;11:5158\u201366.","journal-title":"Clin Cancer Res"},{"key":"3564_CR13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2230.2005.01849.x","volume":"30","author":"P Redondo","year":"2005","unstructured":"Redondo P, Lloret P, Idoate M, Inoges S. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol. 2005;30:541\u20135.","journal-title":"Clin Exp Dermatol"},{"key":"3564_CR14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1385\/MO:22:1:039","volume":"22","author":"F Tas","year":"2005","unstructured":"Tas F, Duranyildiz D, Oguz H, Disci R, et al. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma. Med Oncol. 2005;22:39\u201344.","journal-title":"Med Oncol"},{"key":"3564_CR15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1479-5876-12-19","volume":"12","author":"AA Tarhini","year":"2014","unstructured":"Tarhini AA, Lin Y, Yeku O, et al. A four-marker signature of TNF-RII, TGF-\u03b1, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med. 2014;12:19.","journal-title":"J Transl Med"},{"key":"3564_CR16","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2005.03.7960","volume":"24","author":"H Schmidt","year":"2006","unstructured":"Schmidt H, Johansen JS, Sjoegren P, et al. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol. 2006;24:798\u2013804.","journal-title":"J Clin Oncol"},{"key":"3564_CR17","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s13277-011-0218-x","volume":"32","author":"A D\u00edaz-Lagares","year":"2011","unstructured":"D\u00edaz-Lagares A, Alegre E, Arroyo A, et al. Evaluation of multiple serum markers in advanced melanoma. Tumour Biol. 2011;32:1155\u201361.","journal-title":"Tumour Biol"},{"issue":"7","key":"3564_CR18","doi-asserted-by":"crossref","first-page":"vii86","DOI":"10.1093\/annonc\/mds229","volume":"23","author":"R Dummer","year":"2012","unstructured":"Dummer R, Hauschild A, Guggenheim M, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(7):vii86\u201391.","journal-title":"Ann Oncol"},{"key":"3564_CR19","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.2004.09.112","volume":"22","author":"J Dupont","year":"2004","unstructured":"Dupont J, Tanwar MK, Thaler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol. 2004;22:3330\u20139.","journal-title":"J Clin Oncol"},{"key":"3564_CR20","first-page":"546927","volume":"2012","author":"D Dewing","year":"2012","unstructured":"Dewing D, Emmett M, Pritchard JR. The roles of angiogenesis in malignant melanoma: trends in basic science research over the last 100 years. ISRN Oncol. 2012;2012:546927.","journal-title":"ISRN Oncol"},{"key":"3564_CR21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0304-3835(97)00499-0","volume":"125","author":"J Viac","year":"1998","unstructured":"Viac J, Schmitt D, Claudy A. Circulating vascular endothelial growth factor (VEGF) is not a prognostic indicator in malignant melanoma. Cancer Lett. 1998;125:35\u20138.","journal-title":"Cancer Lett"},{"key":"3564_CR22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.cmr.0000222598.27438.82","volume":"16","author":"F Tas","year":"2006","unstructured":"Tas F, Duranyildiz D, Oguz H, et al. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res. 2006;16:405\u201311.","journal-title":"Melanoma Res"},{"key":"3564_CR23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12032-008-9058-y","volume":"25","author":"F Tas","year":"2008","unstructured":"Tas F, Duranyildiz D, Oguz H, et al. Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Med Oncol. 2008;25:431\u20136.","journal-title":"Med Oncol"},{"key":"3564_CR24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.critrevonc.2003.09.008","volume":"49","author":"E Lambert","year":"2004","unstructured":"Lambert E, Dass\u00e9 E, Haye B, Petitfr\u00e8re E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol. 2004;49:187\u201398.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3564_CR25","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1346-8138.2008.00446.x","volume":"35","author":"Y Yoshino","year":"2008","unstructured":"Yoshino Y, Kageshita T, Nakajima M, et al. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma. J Dermatol. 2008;35:206\u201314.","journal-title":"J Dermatol"},{"key":"3564_CR26","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1158\/1078-0432.CCR-10-2402","volume":"12","author":"HM Kluger","year":"2011","unstructured":"Kluger HM, Hoyt K, Bacchiocchi A, et al. Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res. 2011;12:2417\u201325.","journal-title":"Clin Cancer Res"},{"key":"3564_CR27","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ejca.2011.08.007","volume":"48","author":"F Egberts","year":"2012","unstructured":"Egberts F, Kotthoff EM, Gerdes S, et al. Comparative study of YKL-40, S-100B and LDH as monitoring tools for stage IV melanoma. Eur J Cancer. 2012;48:695\u2013702.","journal-title":"Eur J Cancer"},{"key":"3564_CR28","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1038\/onc.2009.292","volume":"28","author":"R Shao","year":"2009","unstructured":"Shao R, Hamel K, Petersen L, et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene. 2009;28:4456\u201368.","journal-title":"Oncogene"},{"key":"3564_CR29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fphys.2014.00075","volume":"5","author":"V Riabov","year":"2014","unstructured":"Riabov V, Gudima A, Wang N, et al. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol. 2014;5:75.","journal-title":"Front Physiol"},{"issue":"4","key":"3564_CR30","doi-asserted-by":"crossref","first-page":"e95822","DOI":"10.1371\/journal.pone.0095822","volume":"9","author":"J Salamon","year":"2014","unstructured":"Salamon J, Hoffmann T, Elies E, et al. Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice. PLoS One. 2014;9(4):e95822.","journal-title":"PLoS One"},{"key":"3564_CR31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/pcmr.12204","volume":"27","author":"I Helfrich","year":"2014","unstructured":"Helfrich I, Ullrich N, Zigrino P, Schadendorf D. Primary tumor versus metastasis: new experimental models for studies on cancer cell homing and metastasis in melanoma. Pigment Cell Melanoma Res. 2014;27:309\u201316.","journal-title":"Pigment Cell Melanoma Res"},{"key":"3564_CR32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.5021\/ad.2014.26.3.363","volume":"26","author":"JY Jung","year":"2014","unstructured":"Jung JY, Kim HS, Roh MR, et al. The effect of imiquimod on matrix metalloproteinases and tissue inhibitors of metalloproteinases in malignant melanoma cell invasion. Ann Dermatol. 2014;26:363\u201373.","journal-title":"Ann Dermatol"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-3564-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-015-3564-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-3564-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T13:40:19Z","timestamp":1599054019000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-015-3564-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,23]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["3564"],"URL":"https:\/\/doi.org\/10.1007\/s13277-015-3564-2","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,23]]}}}